Nerve growth factor (NGF) is important for regulation, differentiation, and survival of peripheral and central nervous system neurons, including basal forebrain cholinergic neurons (BFCN) which degenerate in Alzheimer's disease (AD). Mature NGF protein is processed from a larger precursor, proNGF. We demonstrate that proNGF is the predominant form of NGF in mouse, rat, and human brain tissue, whereas little or no mature NGF is detected. Previous reports showed NGF protein, measured by ELISA, is increased in AD BFCN target regions such as hippocampus and cortex. Using Western blotting, we demonstrate a twofold increase in proNGF in AD parietal cortex compared to controls, indicating that it is this precursor form, proNGF, that accumulates in AD. This increase may reflect either a role for biologically active proNGF or posttranslational disturbances in NGF biosynthesis that decrease the processing of proNGF to mature NGF in AD.
INTRODUCTION
The objective of this study was to distinguish between the mature and higher molecular weight forms of nerve growth factor (NGF) in the brain and to compare the levels of these forms of NGF in control and Alzheimer's disease (AD) samples. NGF biosynthesis has been extensively studied in the mouse submandibular gland (Fahnestock, 1991) . Murine NGF is translated from two major alternatively spliced transcripts to produce 34 and 27-kDa species; removal of the signal sequence reduces these translation products to proNGF species of 32 and 25 kDa (Selby et al., 1987; Darling et al., 1983; Edwards et al., 1986 Edwards et al., , 1988 . These and higher molecular weight glycosylated NGF precursors have been identified in vitro and in vivo (Berger and Shooter, 1977; Edwards et al., 1988; Dicou et al., 1986; Dicou, 1992; Bresnahan et al., 1990; Lakshmanan et al., 1988; Reinshagen et al., 2000; Seidah et al., 1996) . ProNGF undergoes further post-translational processing to generate a mature product of 13.2 kDa. Human NGF is highly homologous to murine NGF and many of the same proteolytic cleavage sites and glycosylation consensus sites in the mouse sequence are conserved in human NGF (Ullrich et al., 1983) . It has generally been assumed, using mouse submandibular gland as a model, that NGF is largely processed into the mature form and that the mature form accounts for the biological activity in most tissues.
In Alzheimer's disease (AD), neuronal dysfunction and degeneration occur in the basal forebrain cholinergic neurons (BFCN), with reduction in neocortical cholineacetyltransferase (ChAT) activity (Coyle et al., 1983; McGeer et al., 1984; Whitehouse, 1998) . This reduced ChAT activity correlates with the degree of dementia and thus has been regarded as a principal factor associated with the memory loss characteristic of AD (Perry et al., 1978) . NGF, which is synthesized within BFCN target regions, such as the hippocampus and cerebral cortex (Korsching et al., 1985) , maintains survival of the BFCN after injury and regulates cholinergic neurotransmitter levels (Hefti and Weiner, 1986; Scott and Crutcher, 1994; Rylett and Williams, 1994 ; Van der Zee et al., 1995a) . Blocking NGF availability to BFCN results in memory deficits (Chen et al., 1997b; Nitta et al., 1993) . This led to the theory that BFCN degeneration in AD is the result of a deficit in NGF (Appel, 1981) . However, no differences in NGF mRNA expression between AD and controls were found (Jetté et al., 1994; Goedert et al., 1986) . Decreased NGF immunoreactivity in the basal forebrain of AD patients and increased NGF protein in the cerebral cortex and hippocampus have been demonstrated using bioassay and ELISA (Nari-sawa-Saito et al., 1996; Crutcher et al., 1993; Fahnestock et al., 1996; Scott et al., 1995; Mufson et al., 1995) . These changes, along with decreases in trkA expression in AD (Cooper et al., 1994; Hock et al., 1998; Mufson et al., 1996 Mufson et al., , 1997 Salehi et al., 1996) , are consistent with a defect in retrograde transport of NGF in AD brain. However, another possibility suggested by the present study is that defects in posttranslational modification of NGF could reduce the availability of NGF protein to BFCN, thereby decreasing ChAT and trkA levels.
Our approach was to identify the forms of NGF in normal rodent and human brain tissue and in particular, the increased NGF found in AD, using Western blotting. The results show that proNGF is the principal form of NGF in CNS, and that it is increased in AD parietal cortex.
RESULTS

NGF-like Immunoreactivity
To identify mature and precursor NGF immunoreactive forms in postmortem human parietal cortex, Western blot analysis was used with three different antibodies. Purified mouse NGF protein (13 kDa) and mouse submandibular gland (SMG) homogenate containing a 32-kDa band previously identified as proNGF (Darling et al., 1983; Edwards et al., 1986; Seidah et al., 1996) were used as positive controls for NGF immunoreactivity.
A rabbit polyclonal anti-NGF IgG (affinity-purified) raised against whole murine 2.5S NGF, designated MC-51, gave a single band at 32 kDa in human, mouse, and rat brain homogenate; this band comigrated with the 32-kDa proNGF band in mouse SMG homogenate (Fig.  1) . A rabbit polyclonal IgG raised against the first 20 amino acids of the N-terminus of the human mature NGF (Santa Cruz Biotechnology, CA), designated H-20, exhibited immunoreactivity against human parietal cortex homogenates, giving a single band with an apparent molecular weight of 32 kDa corresponding to the proNGF detected by the MC-51 antibody. A third antibody, a polyclonal sheep anti-NGF IgG raised against whole 2.5S murine NGF, also detected the 32-kDa proNGF species in human parietal cortex samples (Fig. 1) .
The specificity of all three antibodies was verified, as shown by example using MC-51. The antibodies were specific for NGF, with no cross-reactivity with BDNF or NT-3 ( Fig. 2A) . Both mature and proNGF bands were eliminated or dramatically reduced by incubation with either 13 kDa NGF (Fig. 2B ) or H-20, the peptide used to raise the antibody. Incubation of these blots with the secondary antibody only resulted in no detectable signal (data not shown), demonstrating these bands are not due to nonspecific binding from the secondary antibody. Therefore, three different antibodies specifically recognize the same 32-kDa proNGF molecule in rodent and human tissues.
Absence of Detectable Mature NGF in Human Cortical Tissue
Mature NGF was not detectable in human brain with any of the antibodies. It should be noted that in both mouse and rat brain, but not human brain, mature NGF was faintly but reproducibly detectable (Fig. 1) . We tested a variety of protocols to confirm that the lack of mature NGF in human cortex was not due to tissue preparation conditions. The buffer did not influence mature NGF yield. Our experiments were carried out in a buffer generally used for the ELISA, to make our results more interpretable in light of published ELISA data. However, we tested a variety of other buffer combinations widely in use for both ELISA and Western assays, including RIPA buffer, low salt buffer, high salt/high detergent buffer, and acid or acid/base treat- and then with HRP-conjugated donkey anti-rabbit secondary antibody at 1:6600 for 1 h at room temperature. Lanes 6 and 7: Primary antibody H-20 was incubated at 1:2000 dilution overnight at 4°C and then with HRP-conjugated donkey anti-rabbit secondary antibody at 1:6600 for 1 h at room temperature. Lanes 8 and 9: Primary sheep antibody was incubated at 1:1000 dilution overnight at 4°C and then with HRP-conjugated donkey anti-sheep secondary antibody at 1:5000 for 1 h at room temperature. ment (Hoener et al., 1996 (Hoener et al., , 1997 Zettler et al., 1996) . None of the assayed conditions resulted in detectable mature NGF in our human samples (data not shown). Furthermore, none of the conditions significantly altered recovery of proNGF.
To determine the lower limit of detection of mature NGF in these experiments, serial dilutions of purified NGF protein were subjected to Western blotting both with and without tissue homogenization. The sensitivity of the assay for purified NGF was as low as 0.013 ng using the polyclonal MC-51 anti-NGF antibody (Fig.  3A) . A similar experiment with H-20 demonstrated that the anti-peptide antibody was 10-fold less sensitive than MC-51 (data not shown). To exclude the possibility that mature NGF was altered in molecular weight by binding to other components in the sample during preparation, we added varying amounts of purified NGF to a standard amount of human tissue prior to homogenization. The added NGF did not increase the amount of proNGF (Fig. 3B) . However, homogenization of added NGF in the presence of tissue reduced the detectable NGF by approximately 40% (Fig. 3C) . NGF was not sequestered in insoluble form, since boiling the pellet in SDS sample buffer following centrifugation of the homogenate recovered a small amount of additional proNGF but no mature NGF. Since 50 g of protein homogenate was loaded per lane in these Western blots and the lower limit of detection in homogenized samples was 0.025 ng NGF, we conclude there is less than 0.025 ng mature NGF per 50 g protein in cortical tissue, or less than 0.5 pg NGF per g protein.
Our human tissue was collected after postmortem intervals of from 4 to 20 h and was then stored frozen at Ϫ80°C prior to use. There was no difference in mature NGF yield between fresh and frozen rat brain (data not shown). To control for degradation of NGF protein during long postmortem intervals, we sacrificed rats and left them at room temperature for 0, 6, and 20 h, the latter two points to simulate a relatively short postmortem interval and the longest postmortem interval of our human subjects. As shown in Fig. 4A , incubation at room temperature for 6 to 20 h did not reduce the amount of mature NGF in rat brain. Although no mature NGF was detectable in human brain, the amount of proNGF was not correlated with postmortem interval for either control (R 2 ϭ 0.17) or AD samples (R 2 ϭ 0.11) or both (R 2 ϭ 0.001) (Fig. 4B ). We tested a variety of human brain regions for NGF, including cortex, hippocampus, and basal forebrain (Fig. 5) . The regions assayed have previously been shown to produce NGF protein as measured by twosite ELISA (Korsching et al., 1985; Scott et al., 1995) . ProNGF was detectable in all samples tested, but no mature NGF was found.
Determination of proNGF Levels in Alzheimer's Disease and Control Samples
Relative levels of proNGF in the parietal cortex of control and AD patients were determined using both the anti-NGF peptide antibody (H-20) and the whole NGF antibody (MC-51). Each of three blots was loaded with two control and two AD parietal cortex samples, 50 -80 g total protein for each sample, depending on the antibody used. Each gel also contained a standard curve consisting of four different total protein concentrations, 25, 50, 75, and 100 g, of one parietal cortex sample common to all blots. Figures 6A-6C(i) show the three blots developed using the H-20 antibody and exhibiting the 32kDa proNGF band. Figures 6A-6C (ii) indicate the 46-kDa ␤-actin immunoreactive band in each sample. ␤-actin was used as an internal control for each of the samples, since its mRNA and protein levels have been demonstrated to remain unchanged between control and AD brain (Takeda et al., 1991 (Takeda et al., , 1992 Holsinger et al., 2000) . Similarly, Figures 
Increased proNGF Levels in Alzheimer's Disease Parietal Cortex
The proNGF immunoreactive band intensity values were normalized to the internal ␤-actin intensity for each sample on all three blots for H-20 antibody and again for MC-51 antibody. The intensities of the proNGF band from both direct measurements and normalized values demonstrated a significant increase in proNGF in the AD samples compared to the controls in both cases. The direct and normalized values between AD and control groups were compared using Student's t test. For the H-20 antibody, the mean value of the AD samples was 2.1 times greater than the control samples with the difference being highly significant (P Ͻ 0.001). Even after normalization of the proNGF band to the internal ␤-actin standard, the average value of the AD samples was 2.1-fold greater than that for the control mean, with the difference between the normalized groups still significant (P ϭ 0.006, Fig. 9A ). For the MC-51 antibody, the difference was somewhat less, but still significant. The mean value of the AD samples was 1.4-fold greater than the control samples both before normalization (P ϭ 0.041) and after normalization (P ϭ 0.047) (Fig. 9B) .
DISCUSSION
Identification of proNGF in Human and Rodent Brain
We have identified an NGF-immunoreactive protein with a molecular weight of 32 kDa in human parietal FIG. 9. Significant increase in intensity of proNGF in AD parietal cortex compared to control, using both direct and normalized values. (A) H-20. n ϭ 6 for each group, P Ͻ 0.001 and P ϭ 0.011 for direct and normalized intensities, respectively. Bars represent mean intensities with Ϯ SEM for each group. (B) MC-51. n ϭ 6 and n ϭ 5 for AD and control groups, respectively, P ϭ 0.041 and P ϭ 0.047 for direct and normalized intensities, respectively. Bars represent mean intensities with Ϯ SEM for each group. cortex. The specificity of the immunoreactivity and the similarity of the 32-kDa band in human, rat, and mouse brain to proNGF from mouse SMG strongly suggests that the 32-kDa band in murine, rat, and human brain is proNGF. Its molecular weight suggests that proNGF from human brain is the product of Transcript A, the same long transcript as in mouse SMG. The same 32-kDa species is recognized by three different polyclonal antibodies, two raised against the entire mature murine NGF molecule, one in rabbit and one in sheep, and the third raised against the first 20 amino acids at the N terminus of the mature human NGF protein. The NGFimmunoreactive band in human tissue is not due to cross-reactivity of the antibodies with BDNF or NT-3 and is specifically blocked by an NGF peptide and by purified murine NGF.
The methods used here do not permit an estimation of the absolute amount of proNGF protein present in human postmortem tissue. Unlike mature NGF, there is no purified precursor standard of known concentration. Furthermore, it is not appropriate to determine amounts of precursor by comparison to mature NGF, because the relative affinities of our antibodies for the NGF precursor compared to mature NGF are unknown. Nevertheless, careful consideration of the linearity of the assay, normalization between blots using a standard brain sample, and normalization to an invariant endogenous protein (␤-actin) allow us to make relative comparisons between samples using Western blotting.
ProNGF Is the Predominant Form of NGF in Human and Mouse Brain
Mature NGF was not detected in human parietal cortex samples with any antibody or with any buffer or extraction condition. ProNGF, but not mature NGF, was detected in a variety of different brain regions. These results are not due to instability of mature NGF in postmortem human brain as compared to proNGF with respect to long postmortem intervals or to freezing: there was no difference in the amount of mature NGF detectable in rodent brain if the tissue was used fresh, frozen before use, or left overnight on the bench to simulate long postmortem intervals, and there was no correlation between postmortem interval and proNGF levels in our human samples. Addition of purified mature NGF to human tissue did not result in its conversion to the 32-kDa form. Nor is it likely that the lack of mature NGF in postmortem human brain was the result of inadequate sensitivity of the method. All three antibodies reacted with 13-kDa recombinant NGF and with the mature NGF protein found in mouse SMG, with a level of detection as low as 0.5 pg NGF per g protein in homogenized tissue. Mouse and rat brain exhibited faint but detectable mature NGF. Furthermore, NGF was weakly detectable in a single human control tissue not used for further study. These results suggest that, if mature NGF were indeed accumulating in AD target tissues to any great extent, it would be detectable using our assay.
Comparison of proNGF Levels in Alzheimer's Disease and Normal Parietal Cortex
We and others have previously demonstrated no differences in NGF mRNA levels between control and AD brains (Jetté et al., 1994; Goedert et al., 1986; Fahnestock et al., 1996) . Previous studies using the two-site ELISA reported an increase in NGF-like immunoreactivity in AD parietal cortex compared to controls (Crutcher et al., 1993; Scott et al., 1995; Fahnestock et al., 1996) . This increase has generally been assumed to be due to accumulation of mature NGF in BFCN target tissues. We show here, through Western blot analysis, that this increase in NGF-like immunoreactivity is very likely due to proNGF. Using two different antibodies, we demonstrate an increase in proNGF in AD compared to control samples. The difference between the two groups is highly significant (P Ͻ 0.001 for the H-20 antibody, and P Ͻ 0.05 for the MC-51 antibody). When the proNGF band intensities were normalized to their internal ␤-actin intensites, a 2.1-fold increase for H-20 and a 1.4-fold increase for MC-51 of the AD samples over the controls was observed (P Ͻ 0.01, P Ͻ 0.05).
In this study, we homogenized the tissue samples in a buffer commonly used for the ELISA assay rather than the usual Western blotting buffers, to render our results more comparable to the previously published ELISA results. The twofold increase we report in proNGF levels in AD is greater than the 15% increases in NGF protein reported by most ELISA studies of AD tissue. This may be due to the presence of interfering substances in the ELISA assay (Zettler et al., 1996) , which are not present when proteins are separated during Western blotting or perhaps due to differences in immunoreactivity of precursor and mature NGF between the Western (solid state) and ELISA (soluble) assays.
ProNGF is commonly thought to be processed to the mature, biologically active NGF prior to secretion. Although we have not established whether the 32-kDa NGF immunoreactive protein detected here is intracellular or secreted, it has been previously shown that secretion of the NGF precursor can occur in cell culture (Mowla et al., 1999; Delsite and Djakiew, 1999) . It is also unclear if the NGF precursor is biologically active or not, since conflicting data have been published supporting both views (Edwards et al., 1988; Ibanez et al., 1992; Chen et al., 1997b) . Increased NGF biological activity has been reported in AD using the neurite outgrowth bioassay (Crutcher et al., 1993) and could arise as a result of either processing of proNGF once the tissue is homogenized or from intrinsic biological activity of the NGF precursor.
Possible Origin of Increased proNGF in AD
The sensitivity of our assay (as little as 0.5 pg mature NGF per g protein) and the detection of mature NGF in one control subject argues against the presence of detectable amounts of mature NGF in normal cortical tissues; it also argues against an accumulation of mature NGF in AD tissues as a result of defective retrograde transport of NGF protein from the cortex and hippocampus to the cell bodies of the BFCN (cf. Scott et al., 1995; Mufson et al., 1995) . Another possibility is that mature NGF is rapidly transported, utilized and cleared from the tissue immediately after processing and secretion. In this case, NGF processing and secretion could be rate-limiting steps in providing biologically active NGF to the BFCN. A third possibility is that proNGF is biologically active, and that this molecule is secreted and retrogradely transported to the BFCN. In support of this, we have detected proNGF (but no mature NGF) in human basal forebrain; others have detected proNGF in rat septum and diagonal band of Broca (Senut et al., 1990) . However, this proNGF cannot be distinguished from endogenous proNGF synthesized by basal forebrain GABAergic neurons (Lauterborn et al., 1995) .
The accumulation of proNGF in AD target tissues reported here indicates there could be a decrease in processing of proNGF in this disease. If so, this might result in reduced availability of mature NGF to BFCN. NGF is known to regulate both cholinergic activity and trkA expression; thus decreased NGF availability may be implicated in the decreased expression of trkA and ChAT in AD (Whitehouse, 1998; Rylett and Williams, 1994; Hock et al., 1998; Kojima et al., 1994 Kojima et al., , 1995 Hagg et al., 1989; Higgins et al., 1989; Li et al., 1995) . A decrease in trkA activity shifts the receptor ratio between trkA and p75 in favor of the latter, which has been shown to suppress trk signalling and can mediate apoptosis of neuronal cells (Kaplan and Miller, 1997) . A decrease in cholinergic function has been shown to lead to cognitive dysfunction (Chen et al., 1997a; Nitta et al., 1993; Van der Zee et al., 1995a) and possibly to increased abnormal APP processing (Felder et al., 1993; Roberson et al., 1997) . Thus, decreased NGF processing may lead to BFCN dysfunction or degeneration in AD.
Summary
We have demonstrated via Western blotting that NGF in mouse, rat, and human brain exists primarily as 32 kDa proNGF, with little or no mature NGF present. We have also demonstrated that proNGF is increased up to twofold in AD parietal cortex compared to controls. This suggests that increased NGF in AD target tissues represents an accumulation of proNGF rather than mature NGF. This proNGF accumulation could be related to cholinergic degeneration in AD.
EXPERIMENTAL METHODS
Antibodies. Antibodies used in this study were as follows: affinity-purified rabbit and sheep polyclonal anti-NGF IgGs raised against murine 2.5S NGF and purified as previously described (Van der Zee et al., 1995b ; also available from Cedarlane Laboratories, Hornby, ON; affinity purified sheep anti-NGF IgG used in initial experiments was a generous gift from Dr. Jack Neurotrophins. Murine recombinant NGF and human recombinant BDNF and NT-3 were expressed in our lab in a baculovirus system and purified by affinity chromatography. Human recombinant NGF was a gift from Genentech (South San Francisco, CA). Murine submandibular gland NGF was prepared as the 2.5S NGF form according to Mobley et al. (1976) and further purified by reverse-phase high performance liquid chromatography (Petrides and Shooter, 1986 ) using a C-18 cartridge in a radial compression module (RCM 8 ϫ 10, Waters, Milford, MA). Human recombinant NGF and murine 2.5S NGF were used interchangeably with recombinant murine NGF as a standard, and none of the antibodies used in this study distinguished between them.
Chemicals and other materials. Hybond-C pure nitrocellulose and PVDF membranes were purchased from Amersham-Pharmacia Biotech (Baie d'Urfé, QUE). Prestained broad-range protein molecular weight markers, precast acrylamide gels, and DC protein assay reagents were from Bio-Rad Laboratories Ltd. (Mississauga, ON, Canada). All other chemicals were reagent grade.
Tissue. Human postmortem brain tissue from AD and normal patients was a generous gift from Dr. Keith Crutcher (University of Cincinnati, Cincinnati, OH). A diagnosis of AD was confirmed in 4 males and 2 females by clinical and pathological criteria, in accordance with the NINCDS-ADRDA guidelines (Khachaturian, 1985; McKhann et al., 1984) . Control tissues were obtained from two male and four female patients without clinical or neuropathological signs of dementia. Mean ages were 73 Ϯ 12.8 (standard deviation) and 80.2 Ϯ 8.7 years for the control and AD patients, respectively. Postmortem delays ranged from 4 to 20 h, with mean delays of 9.8 Ϯ 5.6 and 12.3 Ϯ 6.2 for control and AD, respectively. There were no statistically significant differences between any of these variables for control and AD groups. See Table 1 for sample information.
Human tissue was obtained at autopsy, flash frozen, and stored at Ϫ80°C until use. Mouse submandibular gland and brain tissue were obtained from adult male Swiss-Webster mice (Charles River, St. Constant, Quebec). Mice were killed by CO 2 asphyxiation or decapitation and tissues were immediately dissected out, flash frozen, and stored at Ϫ80°C. Adult Sprague-Dawley or Long-Evans rats (Charles River) were anesthetized with Somnotol and sacrificed by decapitation. Rat brain tissue was dissected out, flash frozen, and stored at Ϫ80°C.
Sample preparation. One gram of tissue was homogenized without thawing using a Polytron homogenizer (Brinkmann, Mississauga, ON) in 5 ml of homogenization buffer (0.5 M Tris-HCl, pH 7.5, 10 mM EDTA, 0.5% Tween 20, 2 g/ml aprotinin, 2 g/ml pepstatin, and 100 g/ml PMSF) on ice. For some experiments, as indicated in the text or figure legends, RIPA buffer (10.8 mM sodium phosphate, pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 2 g/ml aprotinin, 2 g/ml pepstatin, and 100 g/ml PMSF) or other buffers containing high salt or high detergent (Hoener et al., 1996 (Hoener et al., , 1997 Zettler et al., 1996) were substituted for homogenization buffer. The homogenate was incubated 15 min on ice and then centrifuged at 14,000g for 15 min at 4°C, and the supernatants containing solubilized protein were collected. Protein concentrations were determined using the DC protein assay as described by the manufacturer (Bio-Rad Laboratories).
Western blotting. Samples of 50 -80 g each and 0.15-7 ng of NGF protein standard were separated on 4 -20% SDS-polyacrylamide resolving gels (Bio-Rad Laboratories) or 16% SDS-polyacrylamide gels. Proteins were transferred onto Hybond-C nitrocellulose or PVDF membranes in transfer buffer (25 mM Tris, 192 mM glycine, 20% (v/v) methanol) for 2-3 h at 100V or overnight at 30V, at 4°C, and blocked for 1 to 3 h at room temperature or overnight at 4°C in TBS-T (50 mM Tris, pH 8.0, 133 mM NaCl, 0.2% (v/v) Tween 20) with 10% (w/v) Carnation nonfat milk powder. Incubations with primary antibodies were performed for 1 to 2 h at room temperature or overnight at 4°C in TBS-T. After washing in TBS-T, membranes were incubated in HRP-conjugated secondary antibodies in TBS-T with 5% nonfat milk powder for 1 h at room temperature. For detection, an ECL chemiluminescence system (Amersham-Pharmacia) was used according to the manufacturer's instructions. For exact conditions and amounts of antibodies used, please see figure legends.
Densitometry and statistical analysis. Each Western blot contained a standard curve, using a single human cortex sample for all blots, of from 25 to 100 g protein per lane. An amount of protein from unknown samples (both AD and control) was chosen so as to fall within the linear range of the standard curve for both NGF and ␤-actin immunoreactivity. The volume of the immunoreactive bands was determined by densitometry of the films using either an MCID image analysis system (Brock University, St. Catherine's, ON) with the Image Data Analysis software program Northern Exposure, Version 2.0, or with a Microtek Scanner and Scion Image Beta 4.01 Acquisition and Analysis software (Scion Corporation, Frederick, MD). Local background was subtracted. NGF pixel values were normalized to ␤-actin values for each sample. The standard curves for both NGF and ␤-actin immunoreactive bands were 
